Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program

BACKGROUND: The sodium-glucose cotransporter 2 inhibitor canagliflozin has been shown to reduce the risk of cardiovascular and renal events in patients with Type 2 diabetes mellitus and high risk. Pooled analyses of data from early studies and interim data from the CANagliflozin cardioVascular Asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Weir, Matthew R, Slee, April, Sun, Tao, Balis, Dainius, Oh, Richard, de Zeeuw, Dick, Perkovic, Vlado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247742/
https://www.ncbi.nlm.nih.gov/pubmed/34221371
http://dx.doi.org/10.1093/ckj/sfaa133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247742/
https://www.ncbi.nlm.nih.gov/pubmed/34221371
http://dx.doi.org/10.1093/ckj/sfaa133

Ejemplares similares